Pacira BioSciences, Inc. (PCRX) vs Xeris Biopharma Holdings, Inc. (XERS)
- Pacira BioSciences, Inc. PCRX 36.35 +0.06%
- Xeris Biopharma Holdings, Inc. XERS 10.28 +2.09%
Pacira BioSciences, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $1.8B against $1.5B — 1.3× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Pacira BioSciences, Inc. trades at 104×. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 36.3% against 5.71%. Pacira BioSciences, Inc. has the higher net margin (1.96% vs −5.12%) and the lower return on invested capital (1.58% vs 18.9%). Across the 20 metrics below, Pacira BioSciences, Inc. leads on 12 and Xeris Biopharma Holdings, Inc. on 8.
Valuation
Profitability
| Metric | PCRX | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 79.21% | 86.58% | 53.94% |
| Operating margin | 2.66% | 10.91% | 0.00% |
| Net margin | 1.96% | (5.12%) | 0.00% |
| Free cash flow margin | 24.06% | 16.60% | 0.00% |
| Return on equity | 2.05% | 118.22% | (0.40%) |
| Return on assets | 1.05% | (4.60%) | (3.32%) |
| Return on invested capital | 1.58% | 18.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack